Orasis Pharmaceuticals is a pharmaceutical company focused on developing treatments for presbyopia, a condition causing gradual loss of the eye's ability to focus on near objects.

Orasis Pharmaceuticals

Viewport Meta

IPhone / Mobile Compatible

nginx

Microsoft Exchange Online

Office 365 Mail

Google

Google Cloud

Microsoft Azure DNS

CloudFront

Business Management

Paul Smith

Sr. Vice President, Head of Strategy & Marketing

Julie Speed

Associate Director Clinical Operations

Kelly Hall

Director, US Clinical Operations

Laura Trusso

Athan Kuliopulos

Healthcare

Tes Ignacio

Masafuyu Tanaka

Gregory Wertman

Tyler J. Stowater

Yoav Shaked

Elad Kedar

President and Chief Operating Officer

Clinical Trials Companies With Fewer Than 100 Employees

Private Equity Funded Companies (Top 10K)

Venture Capital Funded Companies (Top 10K)

Florida Companies With Fewer Than 100 Employees (Top 10K)

Orasis Pharmaceuticals develops a corrective eye drop to treat presbyopia. The company's product, CSF-1, is an eye drop that improves the quality of life for people with presbyopia by alleviating the burden of reading glasses. By repurposing existing and well-studied molecules, CSF-1 is designed to be effective and also safe, comfortable, and easy-to-use.

Arboretum Ventures

Johnson & Johnson Innovation – JJDC

Series D - Orasis Pharmaceuticals

Catalio Capital Management

Venture Round - Orasis Pharmaceuticals

Bluestem Capital

Visionary Venture Fund

Series C - Orasis Pharmaceuticals

Series B - Orasis Pharmaceuticals

Sequoia Capital Israel

Series A - Orasis Pharmaceuticals

Ponte Vedra

Florida

United States

North America

Presbyopia Treatment Market Set to Reach New Heights with New Therapies and Advancements by 2034 | DelveInsight

Orasis Pharmaceuticals Closes $78M Financing

Orasis Pharmaceuticals Completes $78 Million Financing to Support Commercial Launch of Qlosi™ (pilocarpine hydrochloride ophthalmic solution) 0.4%

FDA Clears Orasis Pharmaceuticals' Presbyopia Treatment

Orasis Pharmaceuticals Announces FDA Approval of QLOSI ...

Orasis Pharmaceuticals Announces FDA Approval of QLOSI™ (pilocarpine hydrochloride ophthalmic solution) 0.4% for ...

FDA approved prescription eye drop for the treatment of presbyopia.

Investigational novel eye drop candidate for the treatment of presbyopia, aiming to improve near vision.

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Oct 15, 2024 8:00 PM	e65e3f14
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Oct 15, 2024 8:00 PM	16e151c9
crunchbase trigger	general	Nov 25, 2024 9:06 AM	c42ab544
crunchbase profile	general	Nov 25, 2024 10:39 AM	864f8d3e
li profile	general
translate crunchbase fundingrounds	general	Nov 25, 2024 4:21 PM	32d2ec8a
peers	general	Oct 15, 2024 8:00 PM	bdd6fc1f
news basic	general	Oct 15, 2024 8:00 PM	7df5da72
bundesanzeiger	filings
financials download nd	financials
private financials	financials

ORAS

COM:ORASIS-PHARMA

Orasis Pharmaceuticals